Last day of trading in subscription rights in IRLAB’s rights issue
Today, 14 July 2025, is the last day of trading in the subscription rights issued in connection with IRLAB Therapeutics AB’s (“IRLAB” or the “Company”) issue of new shares of series A with preferential rights for existing shareholders, which was resolved by the Board of Directors on 24 June 2025 by virtue of the authorization from the Annual General Meeting (the “Rights Issue”). Subscription rights that are not sold by today, 14 July 2025, or exercised for subscription of shares in the Rights Issue no later than 17 July 2025, will expire worthless. Please note that certain banks and nominees may apply an earlier deadline for subscription. Shareholders are therefore advised to check with their bank or nominee regarding any earlier response deadline that may apply.
Read More >IRLAB carries out SEK 136m rights issue
ISP – The proprietary technology platform
IRLAB’s unique and resource efficient research method, the Integrative Screening Process (ISP), generates the company’s drug pipeline. This proprietary platform is built on a systems pharmacology discovery approach with an extensive, world unique, standardized database on CNS compounds and classes collected over 25 years.
IRLAB’s clinical phase II candidates
Mesdopetam (IRL790)
In development to treat levodopa-induced dyskinesia (LIDs), i.e. involuntary movements occurring upon long-term treatment with levodopa in Parkinson’s disease.
Pirepemat (IRL752)
In development to treat impaired balance (postural dysfunction) leading to falls in Parkinson’s disease.
Presentation by Kristina Torfgård, CEO, at Aktiespararna
Presentation by Kristina Torfgård, CEO, at Aktiespararna (in Swedish), held June 10, 2025.
Read More >